适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Sairopa B.V.
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Double-blind, randomized, placebo-controlled, pilot study to evaluate the safety, tolerability and efficacy of two doses of a conditioned medium from a co-culture of M2-macrophages and mesenchymal cells (PRS CK STORM) in the prevention of COVID-19-associated cytokine stormSARS-CoV-2 infectionMedDRA version: 23.0Level: LLTClassification code: 10084272Term: SARS-CoV-2 infection Class: 10021881CTIS2023-507700-32-00Peaches Biotech S.L.50
招募中
1 期
A Phase 1, Open-Label Study to Investigate the TARP-?8 Receptor Occupancy of RAP-219 Using a TARP-?8 PET Tracer in Healthy Adult ParticipantsMedDRA version: 21.0Level: PTClassification code: 10015037Term: Epilepsy Class: 100000004852EpilepsyCTIS2024-512151-21-00Rapport Therapeutics Inc.24
招募中
1 期
A study of STX-721 in participants with non-small cell lung cancer with certain mutationsocally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 21.1Level: LLTClassification code: 10029514Term: Non-small cell lung cancer NOS Class: 10029104CTIS2023-506759-51-00Scorpion Therapeutics Inc.112
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Pharmacokinetics of Single Ascending and Multiple Ascending Doses of Prosetin in Healthy Volunteers and Participants with Amyotrophic Lateral Sclerosis (ALS) with an Optional Open-Label Extended Treatment Period for ALS Participants who Complete 14 Days of Blinded TreatmentCTIS2023-507363-20-00Projenx Inc.24
招募中
1 期
Phase I study evaluating the safety and efficacy of MEDI5752 in combination with stereotactic radiotherapy in patients with metastatic sarcomaMetastatic soft tissue sarcomaCTIS2024-515551-38-00Oncopole Claudius Regaud20